Drug Trial Radar · NCT07813767
THE ROLE OF PANCREATIC STONE PROTEIN (PSP) AND PSP-GUIDED EARLY MEROPENEM TREATMENT TO MITIGATE SEPSIS RISK AT THE EMERGENCY DEPARTMENT: THE PROMISE DOUBLE BLIND, PHASE III, RANDOMIZED CONTROLLED CLINICAL TRIAL
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
398
Planned (sponsor's estimate)
Start
Oct 1, 2026
Primary completion
Sep 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Hellenic Institute for the Study of SepsisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to demonstrate the clinical benefit of early intervention with meropenem in adult patients of both sexes with suspected infection and risk of sepsis. The primary objective is to evaluate the clinical benefit of a protein called Pancreatic Stone Protein (PSP), which, if elevated, indicates that patient may be at increased risk of developing sepsis. The secondary objectives are to investigate the impact of early antibiotic treatment with meropenem on progression to sepsis, survival and mortality. Researchers will compare meropenem to a placebo (a look-alike substance that contains no drug). Participants will: * Take a single dose of meropenem or a placebo * Be evaluated at designated timepoints post administration until their discharge and, also, on days 28 and 90 post administration, respectively.
Conditions
- Sepsis
Interventions
Meropenem InfusionDrug
There is no other intervention in this clinical study and participation in another clinical study is an exclusion criterion.
Sodium Chloride (NaCl) 0.9 %Drug
There is no other intervention in this clinical study and participation in another clinical study is an exclusion criterion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- 28-day mortalityTime frame: 28 days after administration of the study intervention
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Department of Emergency Medicine, G.Gennimatas Athens General Hospital
Athens, Attica, Greece · Recruiting
Department of Emergency Medicine, ATTIKON University General Hospital
Athens, Attica, Greece · Recruiting
Department of Emergency Medicine, Aghios Panteleimon Nikaia General Hospital
Athens, Attica, Greece · Recruiting
Department of Emergency Medicine, Tzaneion Piraeus General Hospital
Piraeus, Attica, Greece · Recruiting
Department of Emergency Medicine, Ioannina University General Hospital
Ioannina, Ioannina, Greece · Recruiting
Department of Internal Medicine, Syros General Hospital
Ermoupoli, Syros, Cyclades, Greece · Recruiting
Department of Emergency Medicine, AHEPA Thessaloniki University General Hospital
Thessaloniki, Thessaloniki, Greece · Recruiting
Department of Emergency Medicine, G. Papanikolaou Thessaloniki General Hospital
Thessaloniki, Thessaloniki, Greece · Recruiting
Department of Emergency Medicine, Koutlibaneio & Triantafylleio General Hospital of Larissa
Larissa, Thessaly, Greece · Recruiting
1st Department of Internal Medicine, Thriasio Eleusis General Hospital
Elefsina, West Attica, Greece · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.